Generic drug makers therefore are competing in the market according to the skills in which they specialize. They specialize in efficient production and distribution of drugs, rather than in developing new drugs.
A generic drug maker can go out of business simply on the basis of not executing their business plan well. However, generic producers have built their business plans around the FDA's current set of regulations. A change in those regulations could have an adverse effect on generic drug makers. For example, if the monopoly protections that come from a new drug approval are extended out further, that would reduce the ability of the generic producer to make money on any given drug. This is especially the case of the drug in question becomes obsolete during the time period prior to the generic having access to that market. In such a situation, the generic maker would not have access to that product during its useful economic life. Such extensions of monopoly protections would have to be across board, since most generic producers make hundreds or even thousands of individual drugs.
4. In conditions of perfect competition, it is conceivable that a firm can earn a profit in the short run. In the short run, a change in the market could result in one or more firms earning a profit. However, these profits will signal to other firms to enter the market. When these other firms enter the market, the profit will no longer exist. This is why it is said that there are no long-run profits in a state of perfect competition.
Margins costs in a state of perfect competition are at a point of marginal prices in the long run. If there is a change in the costs, a firm might be able to temporarily exploit this for a profit, but with perfect information consumers will not stand for this. If there is collusion among sellers, the...
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now